Mr Stocks brings substantial experience and expertise to lead Calistoga Pharmaceuticals’s business and corporate development strategy, and business practices. Mr Stocks will be responsible for corporate/business development, finance
The Female Health Company’s lower-cost second generation female condom will now be available for purchase and distribution in the US. The FDA approval will also enable the US
The company has previously sold these technologies to Solos in February 2007 with the intention of Solos developing the market and revenues for the products. However, Solos’s resources
US-based pharmaceutical company Azaya Therapeutics has announced that it has been selected by the National Cancer Institute for a research collaboration to study Azaya’s lead cancer therapy, ATI-1123.
INT131-007 is a 24 week, high dose active comparator (45mg Actos) and placebo controlled study of INT131 at four doses in poorly controlled type 2 diabetics. According to
Through this validation study, AMDL and Mayo Clinic will perform clinical diagnostic testing to compare AMDL’s DR-70 (FDP) cancer test with a newly developed, next generation test. The
Mount Sinai School of Medicine has been added as a center for the Phase II study because of its reputation in dermatological research. It is anticipated that the
Switzerland-based Basilea Pharmaceutica has announced that the Scottish Medicines Consortium has accepted Toctino for use within National Health Service Scotland for the treatment of adults with severe chronic
Mr Hanson is a founding partner of Barnard Life Sciences, a healthcare consulting company founded in 2001. From 2004 to 2009, Mr Hanson was a member of the
Tolerx, a biopharmaceutical company, has announced that Defend, the Phase III trial of otelixizumab, an investigational novel targeted immunotherapeutic, has started enrollment of new onset autoimmune type 1
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.